HUBB vs LCTX · P/E 28, rev $1.49B vs rev $2.8M
Hubbell Inc (HUBB) versus Lineage Cell Therapeutics Inc (LCTX) — a side-by-side from cached financials, not a winner call.
Hubbell Inc (HUBB) is a electrical equipment & parts company listed on US.
Lineage Cell Therapeutics Inc (LCTX) is a biotechnology company listed on US.
Latest reported HUBB revenue for 2025-12-31 was $1.49B. Net income was $224.2M. Revenue was down 73.5% from 2024-12-31 to 2025-12-31. HUBB currently screens at market cap $22.14B and trailing P/E 28.0.
Latest reported LCTX revenue for 2026-06-30 was $2.8M. Net income was -$3.3M. Revenue was up 62.0% from 2026-03-31 to 2026-06-30. LCTX currently screens at market cap $213.6M.
HUBB currently screens at market cap $22.14B and trailing P/E 28.0. LCTX currently screens at market cap $213.6M.
Not investment advice. Open the HUBB and LCTX stock pages for the full models.
Not investment advice.